AstraZeneca restructures its scandal-plagued China division’s management
Arrest of FTSE 100 pharma group’s country president last year is expected to hit sales
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/7cb45fcd-5a6f-4e2b-9a67-c5a164132883
AstraZeneca has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of its president in the country.
The FTSE 100 group has appointed new executives to lead its Chinese oncology bus...









